Most of the world's surfactants, the workhorse molecules that make things foam, emulsify, and clean, come from petroleum or palm oil. Ruby Bio, a startup in San Carlos, is betting that a naturally occurring yeast can change the unit economics of that swap, turning low-cost sugars into biodegradable ingredients at a scale that finally matters.
Founded in 2022, the company has assembled over $13 million from a syndicate including Alumni Ventures, F4 Fund, and Earth VC [Crunchbase, 2024] [Tracxn, May 2025]. The founders, Charlie Silver and Pavan Kambam, are not newcomers to the hard part of biotech: scaling. Silver previously scaled Mission Bio, a life sciences tools company that raised over $120 million [Startup Intros, 2024]. Kambam, the CTO, led biosynthesis scale-up at Greenlight Biosciences and Clara Foods [Startup Intros, 2024]. Their first public proof point is a fermentation run that moved from 10 liters to 5,000 liters at the Advanced Biofuels and Bioproducts Process Development Unit, a U.S. Department of Energy facility at Lawrence Berkeley National Lab [Saurabh Malani LinkedIn, 2026].
The yeast wedge into a petrochemical market
Ruby Bio's platform uses yeast to convert sugars into biosurfactants, food emulsifiers, and polymer building blocks [Startup Intros, 2024]. The target is a market valued at over $50 billion [Saurabh Malani LinkedIn, 2026]. The company's wedge is a specific strain of yeast, pitched as more efficient and scalable than some bacterial fermentation routes used by competitors. The pitch to manufacturers in personal care, home care, and food is a drop-in, high-performance ingredient that is non-toxic and biodegradable.
A team built for the scale-up grind
In industrial biotech, the gap between a lab breakthrough and a cost-competitive tanker truck is where most ventures stumble. Ruby Bio's leadership is stacked with operators who have navigated that valley before.
- CEO: Scaling DNA. Charlie Silver's track record is in taking complex biotech hardware from prototype to commercial product, having led that motion at Mission Bio and earlier at Novelx and Agilent [Startup Intros, 2024].
- CTO: Fermentation scale. Pavan Kambam's experience at Greenlight Biosciences and Clara Foods involved moving engineered microbes from flasks to production-scale fermenters [Startup Intros, 2024].
- Food science anchor. A key team member, identified as Harshal, brings formulation expertise from Tyson Foods, PepsiCo, and Roquette [Startup Intros, 2024].
The quiet before the commercial storm
The most notable thing about Ruby Bio's public presence is its absence. There is no press fanfare, no named customer announcements, and a careers page with no open roles [Ruby Bio, 2026]. This radio silence points to a deliberate focus on technical de-risking ahead of commercial noise. The 5,000-liter run at a national lab is a classic de-risking milestone, providing data to begin conversations with potential offtake partners.
Those competitors include established players like Locus Fermentation Solutions and Holiferm. The race is not necessarily to be first, but to be cheapest at parity. Ruby Bio's entire bet rests on its yeast strain and process being uniquely capable of that math. For now, the company is a pilot-scale operation with credible founders and a clear target. Its success will be measured in dollars per kilogram.